The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive

Drugs

Volumn 52, Issue 3, 1996, Pages 371-389

  Munglani, Rajesh ^a   Hudspith, Michael J ^a   Hunt, Stephen P ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; RECEPTOR SUBTYPE;

ANALGESIC ACTIVITY; ANOREXIA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; DEPRESSION; EPILEPSY; FEEDING BEHAVIOR; HEART FAILURE; HUMAN; HYPERTENSION; NEUROPSYCHOLOGY; NONHUMAN; PERIPHERAL NERVE INJURY; PERIPHERAL NERVOUS SYSTEM; REVIEW; TRANQUILIZING ACTIVITY;

EID: 0029833456     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652030-00004     Document Type: Review

References (213)

1. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659-60
2. Potter EK. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther 1988; 37; 251-73
3. Grundemar L, Hakanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci 1994; 15: 153-9
4. Colmers WF, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurones. Trends Neurosci 1994; 17: 373-9
5. Wettstein JG, Earley B, Junien JL. Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 1995; 65: 397-414
6. Gehlert DR. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci 1994; 55: 551-62
7. Alien CJ, Koenig JI. Central and peripheral significance of neuropeptide Y and its related peptides. Ann NY Acad Sci 1990; 611:
8. Wahlestedt C, Reis DJ. Neuropetide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 1993; 32: 309-52
9. Herzog H, Hort YJ, Ball HJ, et al. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89: 5794-8
10. 1 type. J Biol Chem 1992; 267: 10935-8
11. Rose PM, Fernandcs P, Lynch J. et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995; 270: 22661-4
12. Rimland J, Xin W, Sweetnam P, et al. Sequence and expression of a neuropeptide Y receptor cDNA. Mol Pharmacol 1991; 40: 869-75
13. Jazin EE, Yoo H, Blomqvist AG, et al. A proposed bovine neuropeptide Y ( NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. Regul Pept 1993; 47: 247-58
14. Bard JA, Walker MW, Branchek TA, et al. Cloning and characterisation of a novel human neuropeptide Y/peptide YY/pancreatic peptide receptor subtype (Y4) [abstract]. Soc Neurosci 1995; 21: 1012
15. 2 type of NPY receptors [abstract]. Soc Neurosci 1995; 21: 1593
16. Fuxe K, Agnati LF, Harfstrand A, et al. On the role of neuropeptide Y in information handling in the central nervous system in normal and physiopathological states. Focus on volume transmission and neuropeptide Y/alpha2 receptor interactions. Ann N Y Acad Sci 1990; 579: 28-67
17. Tabarin A, Cassiede P, Minot AP, et al. Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities. Acta Endocrinol 1993; 128: 243-50
18. Michel MC, Buschauer A. Neuropeptide Y and its antagonists. Drugs Future 1992; 17: 39-45
19. WestlindDanielsson A, Unden A, Abens J, et al. Neuropeptide Y receptors and the inhibition of adenylate cyclase in the human frontal and temporal cortex. Neurosci Lett 1987; 74: 237-42
20. 1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Letters 1990; 260: 73-8
21. Wiley JW, Gross RA, Macdonald RL. Agonists for neuropeptide Y receptor subtypes NPY-1 and NPY-2 have opposite actions on rat nodose neuron calcium currents. J Neurophysiol 1993; 70: 324-30
22. 125I] neuropeptide Y binding sites in the rat spinal cord and the effects of neonatal capsaicin, dorsal rhizotomy and peripheral axotomy. Brain Res 1992; 574: 333-7
23. Mantyh PW, Allen CJ, Rogers S, et al. Some sensory neurones express neuropeptide Y receptors: potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injury. J Neurosci 1994; 14: 3958-68
24. 2+ currents in rat sensory neurons. J Neurosci 1988; 8: 2438-46
25. Hirning LD, Fox AP, Miller RJ. Inhibition of calcium currents in cultured myenteric neurons by neuropeptide Y: evidence for direct receptor/channel coupling. Brain Res 1990; 532: 120-30
26. 2+ currents by neuropeptide Y. J Neurosci 1988;8:2447-51
27. 1 receptors in the rat nervous system with special reference to Somatic receptors on small dorsal root ganglion neurons. Proc Natl Acad Sci USA 1994; 91: 11738-42
28. 4 receptors [abstract]. Soc Neurosci 1995; 21: 1596
29. Brown BJ. Neuronal localisation of neuropeptide Y gene expression in the rat brain. J Comp Neurol 1989; 290: 358-68
30. Dawbarn D, Hunt SP, Emson PC. Neuropeptide Y: regional distribution, Chromatographic characterization and immunohislochemical demonstration in post-mortem human brain. Brain Res 1984; 296: 168-73
31. Hunt SP, Emson PC, Gilbert R. et al. Presence of avian pancreatic polypeptide-like immunoreactivity in catecholamine and methionine-enkephalin-containing neurones within the central nervous system. Neurosci Lett 1981; 21: 125-30
32. Allen JM, Gibson SJ, Adrian TE, et al. Neuropeptide Y in human spinal cord. Brain Res 1984; 308: 145-30
33. Gray TS, Morley JE, Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous system. Lite Sci 1986; 38: 389-401
34. Lundberg JM, FrancoCereceda A, Lacroix JS, et al. Neuropeptide Y and sympathetic neurotransnmission. Ann NY Acad Sci 1990; 611: 166-74
35. Pernow J, Schwieler J, Kahan T, et al. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am J Physiol Heart Circ Physiol 1989; 257: H866-72
36. Haass M, Cheng B, Richardt G, et al. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 71-8
37. Pernow J, Lundberg JM. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha2, NPY and angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 379-85
38. 2 receptors inhibit [3H]nor-adrenaline release from rat hypothalamic synaptosomes via different mechanisms. Neurosci Lett 1995; 188: 9-12
39. Gibson SJ, Polak JM, Allen JM, et al. The distribution and origin of a novel brain peptide, neuropeptide Y in the spinal cord of several mammals. J Comp Neurol 1984; 227: 78-91
40. Ghilardi JR, Allen CJ, Vigna SR, et al. Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons. Brain Res 1994; 633: 33-40
41. Doyle CA, Maxwell DJ. Direct catecholaminergic innervation of the spinal dorsal horn with axons ascending in the dorsal columns, in the cat. J Comp Neurol 1993; 331: 434-44
42. Doyle CA, Maxwell DJ. Neuropeptide Y-immunoreactive terminals form axo-axonic synatic arrangements in the substantia gelatinosa (lamina II) of the cat spinaldorsal horn. Brain Res 1993; 603: 157-61
43. Doyle CA, Maxwell DJ. Light and electron-microscopic analysis of neuropeptide Y immunoreactive profiles in the cat spinal dorsal horn. Neuroscience 1994; 61: 107-21
44. Rowan S, Todd AJ, Spike RC. Evidence that neuropeptide Y is present in GABAergic neurons in the superficial dorsal horn of the rat spinal cord. Neuroscience 1993; 53: 537-45
45. Castro-Lopes JM, Tavaras I, Tolle TR, et al. Increase in GABAergic cells and GABA levels in the spinal cord in unilateral inflammation in the hind limb in the rat. Eur J Neurosci 1992; 4: 296-301
46. Barber RP, Vaughn JE, Sailto K, et al. GABAergic terminals are presynaptic to primary afferent terminals in the substantia gelatinosa of the rat spinal cord. Brain Res 1978; 141: 35-55
47. Sheikh SP, Holst JJ, SkakNielsen T, et al. Release of NPY in pig pancreas: Dual parasympathetic and sympathetic regulalion. Am J Physiol Gastrointest Liver Physiol 1988; 255: G46-54
48. Dinnorit Y, Fournier A, StPierre S, et al. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 1993; 13: 73-86
49. 1 receptor/G protein system in rat brain cortex. Am J Physiol Regul Integr Comp Physiol 1995; 268: R192-200
50. 2 radioligands. J Pharmacol Exp Ther 1995; 272: 673-80
51. 2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 546-8
52. Kombian SB, Colmers WF. Neuropeptide Y selectively inhibits slow synaptic potentials in rat dorsal raphe nucleus in vitro by a presynaptic action. J Neurosci 1992; 12: 1086-93
53. 2 receptor. Br J Pharmacol 1991; 102: 41-4
54. Roman FJ, Pascaud X, Duffy O. et al. N-Methyl-D-aspartate receptor complex modulation by neuropeptide Y and peptide YY in rat hippocampus in vitro. Neurosci Lett 1991; 122: 202-4
55. Colmers WF. Modulation of synaptic tranmission in hippocampus by neuropeptide Y: presynaptic actions. Ann NY Acad Sci 1990; 611: 206-18
56. Monnet FP, Fournier A, Debonnel G, et al. Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus: I. Involvement of an atypical neuropeptide Y receptor. J Pharmacol Exp Ther 1992; 263: 1212-8
57. Monnet FP, Debonnel G, Fournier A, et al. Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus: II. Involvement of a subtype of sigma receptor. J Pharmacol Exp Ther 1992; 263: 1219-25
58. Monnet FP, Debonnel G, Bergeron R, et al. The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussis toxin. Br J Pharmacol 1994; 112: 709-15
59. Potter EK, Mitchell L, McCloskey MJD, et al. Pre- and postjunctional actions of neuropeptide Y and related peptides. Regul Pept 1989; 25: 167-77
60. Grundemar L, Grundstrom N, Johansson IGM, et al. Suppression by neuropeptide Y of capsaicin-sensitive sensory nerve-mediated contraction in guinea-pig airways. Br J Pharmacol 1990; 99: 473-6
61. Grundemar L, Wahlestedt C, Wang ZY. Neuropeptide Y suppresses the neurogenic inflammatory resonse in the rabbit eye; mode of action. Regul Pept 1993; 43: 57-64
62. Bendotti C, Vezzani A, Tarizzo G, et al. Increased expression of GAP-43, somatostatin and neuropeptide Y mRNA in the hippocampus during the development of hippocampal kindling in rats. Eur J Neurosci 1993; 5: 1312-20
63. Rizzi M, Monno A, Samanin R, et al. Electrical kindling of the hippocampus is associated with functional activation of neuropeptide Y - containing neurons. Eur J Neurosci 1993; 5: 1534-8
64. Fukui K, Kawashima Y, Iizumi H, et al. Iminunohistochemical alterations in neuropeptide Y - positive nerve elements in rat cerebral cortex following acute phencyclidine treatment. Neuroreport 1995; 6: 626-8
65. Nawa H, Bessho Y, Carnahan J, et al. Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor. J Neurochem 1993; 60: 772-5
66. Nawa H, Carnahan J, Call C. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. Eur J Neurosci 1995; 7: 1527-35
67. Mizuno K, Curnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-56
68. Croll SD, Wiegand SJ, Anderson KD, et al. Regulation of neuropeptidcs in adult rat forebrain by the neurotrophins BDNF and NGF. Eur J Neurosci 1994; 6: 1343-53
69. Lapchak PA, Araujo DM. Effects of chronic intraventricular nerve growth factor treatment on vasoactive intestinal peptide and neuropeptide Y levels in the hippocampal formation and cerebral cortex following fimbrial transections. Brain Res 1994; 654: 1-7
70. Jones KR, Farinas I, Backus C, et al. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 1994; 76: 989-99
71. Zhou XF, Rush RA. Sympathetic neurons in neonatal rats require endogenous neurotrophin-3 for survival. J Neurosci 1995; 15: 6521-30
72. Nawa H, Pelleymounter MA, Carnahan J. Intraventricular administration of BDNF increases neuropeptide expression in newborn rat brain. J Neurosci 1994; 14: 3751-65
73. Verge VMK, Richardson PM, WiesenfeldHallin Z, et al. Differential influence of nerve growth factor on neuropeptide expression in viva: a novel role in peptide suppression in adult sensory neurons. J Neurosci 1995; 15: 2081-96
74. Allen JM, Tischler AS, Lee YC, et al. Neuropeptide Y (NPY) in PC12 phaeochromocytoma cultures: responses to dexamethasone and nerve growth factor. Neurosci Lett 1984; 46: 291-6
75. Sabol SL, Higuchi H. Transcriptional regulation of the neuropeptide Y gene by nerve growth factor: antagonism by adenosine 3',5'-monophosphate and phorbol ester. Mol Endocrinol 1990; 4: 384-92
76. Milner P, Crowe R, Fernyhough P, et al. Nerve growth factor treatment of adull rats selectively enhances innervation of urinogenital tract rather than vascular smooth muscle. Int J Dev Neurosci 1995; 13: 393-401
77. Oswald RJ, Byers MR. The injury response of pulpal NPY-IR sympathetic fibers differs from that of sensory afferent fibers. Neurosci Lett 1993; 164: 190-4
78. Tuttle JB, Steers WD. Nerve growth factor responsiveness of cultured major pelvic ganglion neurons from the adult rat. Brain Res 1992; 588: 29-40
79. Rao MS, Tyrrell S, Landis SC, et al. Effects of ciliary neurotrphic factor (CNTF) and depolarization on neuropeptide expression in cultured sympathetic neurons. Dev Biol 1992; 150: 281-93
80. Friedman B, Scherer SS, Rudge JS, et al. Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo, Neuron 1992; 9: 295-305
81. Barnca A, Cho G, Lu G. Role for glial cells in regulating the functional expression of neuropeptide Y (NPY) neurons in aggregate cultures derived from dissociated fetal brain cells. J Neurosci Res 1994; 38: 459-67
82. Lerchen RA, Yum DY, Krajcik R, et al. Transcriptional vs posttranscriptional control of neuropeptide Y gene expression. Endocrinology 1995; 136: 833-41
83. Li JY, Hou XE, Dahlstrom A. GAP-43 and its relation to autonomic and sensory neurons in sciatic nerve and gastrocnemius muscle in the rat. J Auton Nerv Syst 1995; 50: 299-309
84. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996 May 30;381: 415-8
85. Shigeri Y, Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 1993; 149: 19-22
86. Garcia De Yebenes E, Li S, Fournier A, et al. Regulation of proopiomelanocotin gene expression by neuropeptide Y in the rat arcuate nucleus. Brain Res 1995; 674: 112-6
87. Wallengren J, Ekman R, Sundler F. Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venereol 1987; 67: 185-92
88. Lincoln J, Milner P, Appenzeller O. et al. Innervation of normal human sural and optic nerves by noradrenaline- and peptide-containing nervi vasorum and nervorum: effect of diabetes and alcoholism. Brain Res 1993; 632: 48-56
89. Unsicker K, Stogbauer F, Screening of adrenal medullary neuropeptides for putative neurotrophic effects, Int J Dev Neurosci 1992; 10: 171-9
90. White DM. Neuropeptide Y and vasoactive intestinal peptide act indirectly to enhance neurite outgrowth of cultured rat sensory neurons [abstract], 11th World Congress of Anaesthesiologists; 1996 Apr 14-20; Sydney, 313
91. Spitsbergen JM, Stewart JS, Tuttle JB. Altered regulation of nerve growth factor secretion by cultured VSMCs from hypertensive rats. Am J Physiol Heart Circ Physiol 1995; 269: H621-8
92. Hua XY, Boublik JH, Spicer MA. et al. The antinociceptive effect of spirally administered neuropeptide Y: systemic studies on structure-activity relationships. J Pharmacol Exp Ther 1991; 258: 243-8
93. Mellado M, Gilbert-Rahola J, Lagares R. et al. Dual actions of NPY on nociception in mice. In: Allen J, Cox HM. editors. Neuropeptide Y. Cambridge. England. 1993: A21
94. De KY, Henry JL. Substance P - mediated slow excitatory post-synaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. Proc Natl Acad Sci USA 1991; 88: 11344-8
95. Zhang X, WiesenfeldHallin Z, Hokfelt T. Effect of peripheral axotomy on expression of neuropeptide Y receptor mRNA in rat lumbar dorsal root ganglia. Eur J Neurosci 1994; 6: 43-57
96. 2+ channels in sensory neurons. Proc Natl Acad Sci USA 1988; 85: 3633-7
97. Duggan AW, Hope PJ, Lang CW. Microinjection of neuropeptide Y into the superficial dorsal horn reduces stimulus evoked release of immunoreactive substance P in the anaesthetized cat. Neuroscience 1991; 44: 733-40
98. Pich EM, Solfrini V, Marrama P. et al. Centrally administered neuropeptide Y fails to increase food intake but enhances hypoalgesia in spontaneously hypertensive rats. Neurosci Lett 1993; 149: 209-12
99. Fine K, Agnati LF, Harfstrand A, et al. On the role of neurupeptide Y in information handeling in the central nervous system in normal and physiopathalogical states. Ann NY Acad Sci 1990; 579: 28-67
100. Liu H, Brown JL, Jasmin L, et al. Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci USA 1994; 91: 1009-13
101. Zhang X, Meister B, Elde R, et al. Large calibre primary afferent neurons projecting to the gracile nucleus express neuropeptide Y: an immunohistochemical and in situ hybridisation study in rats. Eur J Neurosci 1991; 5: 1510-9
102. Wakisaka S, Kajander KC, Bennett GJ. Increased neuropeptide Y (NPY)-like immunoreactivity in rat sensory neurons following peripheral axotomy. Neurosci Lett 1991; 124: 200-3
103. Frisen J, Risling M, Theodorsson E, et al. NPY-like immunoreactivity in sensory nerve fibers in rat sciatic neuroma. Brain Res 1992; 577: 142-6
104. Noguchi K, De Leon M, Nahin RL. et al. Quantification of axotomy-induced alteration of neuropeptide mRNAs in dorsal root ganglion neurons with special reference to neuropeptide Y mRNA and the effects of neonatal capsaicin treatment. J Neurosci Res 1993; 35: 54-66
105. Roberts W. A hypothesis on the physiological basis of causalgia and related pains. Pain 1986; 24: 297-311
106. Woolf CJ, Doubell TP. The pathophysiology of chronic pain-increased sensitivity to low threshold Aβ-fibre inputs. Curr Opin Neurobiol 1994; 4: 525-34
107. Toth P, Bindokas V, Bleakman D, et al. Mechanism of pre-synaptic inhibitionby neuropeptide Y al sympathetic nerve terminals Nature 1993; 364: 635-8
108. McLachlan EM, Janig W, Devor M, et al. Pheripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363: 543-5
109. Munglani R, Bond A, Smith G. et al. Changes in neuronal markers in a mononeuropathic rat model: relationship between neuropeptide Y, pre-emptive drug treatment and long term mechanical hyperalgesia. Pain 1995; 63: 21-31
110. Munglani R, Harrison S, Smith G, et al. Persistent changes in neuronal markers in a mononeuropathic rat model despite resolution of mechanical hyperalgesia [abstract]. Brain Res Assoc 1995; 12: 76
111. Bennett GJ, Xie Y-K. A peripheral neuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-108
112. Munglani R, Harrison S, Smith G. et al. Effect of different preemptive treatments on long-term neuropeptide expression in the dorsal root ganglia in a model of neuropathic pain. Br J Anaesth 1995; 74: 482P
113. Jenkins R, Hunt SP. Long-term increase in the levels of c-jun mRNA and Jun protein-like immunoreactivity in motor and sensory neurons following axon damage. Neurosci Lett 1991; 129: 107-10
114. Jenkins R, McMahon SB, Bond AB, et al. Expression of c-Jun as a response to dorsal root and peripheral nerve section in damaged and adjacent intact primary sensory neurons in the rat. Eur J Neurosci 1993; 5: 751-9
115. Wakisaka S, Sasaki Y, Kurisu K. Temporal analysis of neuropeptide Y expression in the rat trigeminal ganglion following peripheral axotomy of the inferior alveolar nerve. Neurosci Lett 1995; 188: 49-52
116. Munglani R, Christadoulou E, Fleming B, et al. Peripheral neuropathy causes the expression of NPY in a population of neuronal cell bodies distinct from diaphorase postive neuronal cell bodies in the dorsal root ganglia [abstract]. Brain Res Assoc 1995; 12: 75
117. Morris R, Southam E, Braid DJ, et al. Nitric oxide may act as a messenger between dorsal root ganglion neurones and their satellite cells. Neurosci Lett 1992; 137: 29-32
118. Verge VMK, Xu Z, Xu X, et al. Marked increases in nitric oxide synthase mRNA in rat dorsal root ganglia after peripheral axotomy: In situ hybridisation and functional studies Proc Natl Acad USA 1992; 89: 11617-21
119. Kowall NW, Ferrante RJ, Beal MF, et al. Neuropeptide Y. somatostatin. and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study Neuroscience 1987; 20: 817-28
120. Munglani R, Hunt S. Molecular biology of pain. Br J Anaesth 1945; 75: 186-92
121. Millan MJ. Multiple opioid systems and chronic pain. In: Herz A. Akil H. Simon EJ, editors Opioids II. Berlin: Springer-Verlag. 1993: 127-62
122. Wakisaka S, Kajander KC, Bennett CJ. Effects of pheripheral nerve injuries and tissue inflammation on the levels of neuropeptide Y-like immunoreactivity in rat primary affent neurons. Brain Res 1992; 598: 349-52
123. 1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J Neurosci 1994; 14: 6423-34
124. Zhang X, Wiesenfeld Hallin Z, Hokfelt T. Effects of peripheral axotomy on expression of neuropeptide Y receptor mRNA in rat lumbar dorsal root ganglia. Eur J Neurosci 1994; 6: 43-57
125. Levine J. Fields H, Basbaum A. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13: 2273-86
126. Sato J. Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991; 251: 1608-10
127. Devor M, Janig W. Activation of myelinated afferents ending in a neuroma by stimulation of the sympathetic supply in a rat. Neurosci Lett 1981; 24: 43-7
128. Edvinsson L, Ekblad E, Hakanson R. et al. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1984; 83: 519-25
129. Tracey DJ, Romm MA, Yao NNL. Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y Brain Res 1995; 669: 245-54
130. Claxson A, Morris C, Blake D. et al. The anti-inflammatory effects of D-myo-inositol 1,2,6-trisphosphate (PP56) on animal models of inflammation. Agents Actions 1990; 29: 68-70
131. Feth F, Erdbrugger W, Rascher W, et al. Is PP56 (D-myo-inositol-1,2,6-triphosphate ) an antagonist at neuropeptide Y receptors? Life Sci 1993; 52: 1835-44
132. Lindh B, Hokfelt T, Elfvin LG, et al. Topography of NPY-, somatostatin-, and VIP-immunoreactive. neuronal sub-populations in the guinea pig celiac-superior mesenteric ganglion and their projection to the pylorus J Neurosci 1986; 6: 2371-83
133. Basbaum AI, Fields HL. Endogenous pain control systems: brain stem spinal pathways and endorphin circuitry. Ann Rev Neurosci 1984; 7: 309-88
134. Doyle CA, Maxwell DJ. Catecholaminaergic innervation of the spinal dorsal horn: a correlated light and electron microscopic analysis of tyrosine hydroxylase-immunoreactive fibres in the cat. Neuroscience 1991; 45: 161-76
135. Anand P. Nerve growth factor regulates nociception in human health and disease. Br J Anaesth 1995; 75: 201-8
136. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353-9
137. Andreev NY, Dimitrieva N, Koltzenburg M, et al. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995; 63: 109-15
138. Tracey DJ, Romm MA, Yao NNL. Peripheral hyperalgesia in experimental neuropathy: excerbation by neuroeptide Y. Brain Res 1995; 669: 245-54
139. Levine JD, Taiwo YO, Collins SD, et al. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature 1986; 323: 158-60
140. Vanos DN, Ramamurthy S, Hoffman J. Intravenous regional block using Ketorolac: preliminary results in the treatment of reflex sympathetic dystrophy. Anaesth Analg 1992; 74: 139-41
141. Larsson J, Ekhlom A, Henriksson K. et al. Concentration of substance P, neurokinin A, calcitonin gene related peptide. neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991; 20: 326-35
142. Kozin F, McCarty D, Sims J, et al. The reflex sympathetic dystrophy syndrome. Am J Med 1976; 60: 321-31
143. Stanley BG, Leibowitz SF. Neuropeptide Y: sof feeding and drinking by injection into the paraventricular nucleus. Life Sci 1984; 35: 2635-42
144. Akabayashi A, Wahlestedt C, Alexander JT, et al. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Mol Brain Res 1994; 21: 55-61
145. Minami S, Kamagai J, Sugihara H, et al. Central glucodeprivation evoked by the administration of 2-deoxy-D-glucose induces expression of the c-fos gene in a sub population of neuropeptide Y neurones in the rat hypothalamus. Mol Brain Res 1995; 33: 305-10
146. Rogers P. McKibbin PE, Williams G. Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat: possible implications for the anorectic effect of fenfluramine. Peptides 1991; 12: 251-5
147. Kaye WH, Berrettini WH, Gwirtsman HE, et al. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactvity in anorexia and bulimia nervosa. Arch Gen Psychiatry 1990; 47: 548-56
148. McCarthy HD, Kilpatrick AP, Trayhurn P, et al. Widespread increases in regional hypothalamic neuropeptide Y levels in acute cold exposed rats. Neuroscience 1993; 54: 127-32
149. Saladin R, De Yos P, GuenueMillo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-9
150. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530-2
151. Clark JT, Sahu A, Mrotek JJ, et al. Sexual function and neuropeptide Y levels in selected brain regions in male spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 1991; 261: R1234-41
152. Poggioli R, Vergoni AV, Marrama D, et al. NPY-induced inhibition of male copulatory activity is a direct behavioural effect. Neuropeptides 1990; 16: 169-72
153. Clark JT, Benextramine, a putative neuropeptide Y receptor antagonist, attenuates the termination of receptivity. Physiol Behav 1992; 52: 965-9
154. Heilig M, Koob GF, Ekman R, et al. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 1994; 17: 80-5
155. 1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528-31
156. Widerlov E, Lindstrom LH, Wahlestedt C, et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988; 22: 69-79
157. Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1992; 59: 73-80
158. Wahlestedt C, Karoum F, Jaskiw G, et al. Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. Proc Natl Acad Sci USA 1991; 88: 2078-82
159. Kataoka Y, Sakurai Y, Mine K, et al. The involvement of neuropeptide Y in the antimuricide action of noradrenaline injected into the medial amygdala of olfactory bulbectomized rats. Pharmacol Biochem Behav 1987; 28: 101-3
160. Frederiksen SO, Ekman R, Gottfries CG, et al. Reduced concentrations of galanin, arginine vasopressin. neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 1991; 83: 273-7
161. Sakai K, Maedea K, Chiara K, et al. Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol depot treatment in rats. Neuropeptides 1995; 29: 157-61
162. Flood JF, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y. Brain Res 1987; 421: 280-90
163. Flood JF, Baker ML, Hernandez EN, et al. Modulation of memory by neuropeptide Y varies with brain injection site. Brain Res 1989; 503: 73-82
164. Morley JE, Flood JF. Neuropeptide Y and memory processing. Ann NY Acad Sci 1990; 611: 226-31
165. Beal MF, Mazurek MF, Chattha GK, et al. Neuropeptide Y immunoreactvity is reduced in cerebral cortex in Alzheimers's disease. Ann Neurol 1985; 20: 282-8
166. Allen JM, Ferrier IN, Roberts GW, et al. Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia. J Neurol Sci 1984; 64: 325-31
167. Gabriel S, Bierer L, Harotunin V, et al. Widespread deficits in somatostatin but not NPY concentrations in Alzheimers's disease cerebral cortex. Neurosci Lett 1993; 155: 116-20
168. Phillips HS, Hains JM, Armanini M, et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimers's disease. Neuron 1991; 7: 695-702
169. Michel MC, Rascher W, Neuropeptide Y: a possible role in hypertension? J Hypertens 1995; 13: 385-95
170. Shine J, Potter EK, Biden T, et al. Neuropeptide Y and regulation of the cardivascular system. J Hypertens 1994; 12: S41-5
171. Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 1986; 13: 307-18
172. Grundemar L, Jones SE, Morner N, et al. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol 1992; 105: 45-50
173. Modin A, Pernow J, Lundberg JM. Evidence for two neuropeptide Y receptors mediating vasoconstriction. Fur J Pharmacol 1991; 203: 161-71
174. 2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides 1993; 25: 289-98
175. Benarroch EE, Schmelzer JD. Ward KK, et al. Noradrenergic and neuropeptide Y mechanisms in guanethidine-sympathectomized rats. Am J Physiol Regul Integr Comp Physiol 1990; 259: R371-5
176. Girundemar L, Hakanson R. Multiple neuropeptide Y receptors are involved in cardiovascular regulation: peripheral and central mechanisms. Gen Pharmacol 1993; 24: 785 96
177. Han C, Abel PW. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol 1987; 9: 675-81
178. Macrae IM, Dewar D, Reid JL, et al. Specific alterations in cardiovascular function and in glucose utilisation within lower brainstem nuclei following intracisternal neuropeptide Y in the conscious rat. Brain Res 1990; 515; 99-103
179. Grundemar L, Wahlestedt C, Reis DJ. Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor retlex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. Nemosci Lett 1991; 122: 135-9
180. Shih CD, Chan JYH, Chan SHH. Tonic suppression of baroreceptor reflex response by endogenous neuropeptide Y at the nucleus tractus solitarius of the rat. Neurosci Lett 1992; 148: 169-72
181. McAuley MA, Macrae IM, Reid JL. The cardiovascular actions of clonidine and neuropeptide-Y in the ventrolateral medulla of the rat. Br J Pharmacol 1989; 97: 1067-74
182. 1 receptor agonist. Brain Res 1993; 621: 126-32
183. 2 receptors in the nucleus tractus solitarii of the rat: a cardiovascular and quantitative receptor autoradiographical analysis. Brain Res 1994; 654: 137-44
184. Yang SN, Fior DR, Hedlund PB, et al. Comjections of NPY(1-36) or (Leu31,Pro34)NPY with adrenaline in the nucleus tractus solitarius of the rat counteract the vasodepressor responses to adrenaline. Neurosci Lett 1994; 171: 27-31
185. 2 receptor agonists. Neuroreport 1995; 6: 384-8
186. Maisel AS, Scott NA, Motulsky HJ, et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 1989; 86: 43-8
187. Ullman B, FrancoCereceda A, Hulting J, et al. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med 1990; 228: 583-9
188. Solt V, Brown M, Kennedy B, et al. Elevated insulin, norepinephrine and neuropetide Y in hypertension. Am J Hypertens 1990; 3: 823-8
189. Lettgen B, Wagner S, Hanze J, et al. Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. J Hum Hypertens 1994; 8: 345-9
190. Wocial B, IgnatowskaSwitalska H, Pruszezyk P, et al. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 1495; 4: 143-7
191. Lundberg JM, Hemsen A, Fried G, et al. Co-release of neuropeptide Y (NPY)-like immunoreactivity and catecholamines in new born infants. Acta Physiol Scand 1986; 126: 471-3
192. Lundberg JM, Rudehill A, Sollevi A, et al. Frequency- and reserpine-dependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett 1986; 63: 96-100
193. Lemne CE, Lundberg T. Theodorsson E, et al. Increased basal concentrations of plasma endothelin in borderline hypertension. J Hypertens 1994; 12: 1069-74
194. 1 receptors, Eur J Pharmacol 1994; 271: 265-71
195. Rudehill A, Sollevi A, FrancoCereceda A, et al. neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides 1986; 7: 821-6
196. Michel MC, Wirth SC, Zerkowski HR, et al. Lack of inotropic effects of neuropeptide Y in human myocardium. J Cardiovasc Pharmacol 1989; 14: 919-22
197. Hulting J, Sollevi A, Ullman B, et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990; 24; 102-8
198. Ullman B, Jensen-Urstad M, Hulting J, et al. Neuropeptide Y. noradrenaline and invasive haemodynamic data in mild to moderate chronic congestive heart failure. Clin Physiol 1993; 13: 409-18
199. Omland T, Opstad PK, Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J 1994; 127: 774-9
200. Feng QP, Hedner T, Andersson B, et al. Cardiac neuropetide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994; 71: 261-7
201. Kahan T, Taddei S, Pedrinelli R, et al. Nonadrenergic sympathetic vascular control of the human forearm in hypertension: possible involvement of neuropeptide Y. J Cardiovasc Pharmacol 1992; 19: 587-92
202. 1 receptor agonist. Proc Natl Acad Sci USA 1990; 87: 182-6
203. Dhanoa DS, Neuropeptide Y: a promising therapeutic target. Exp Opin Ther Patents 1995; 5: 391-6
204. 1 receptor antagonist: BIBP 3226. Eur J Pharmacol 1994; 271: R11-3
205. 1 receptor antagonist. FEBS Lett 1995; 362: 192-6
206. 1-type receptor. J Med Chem 1995; 38: 1150-7
207. Grouzmann E, Cressier F, Walker P, et al. Interactions between NPY and its receptor: assessment using anti-NPY antibodies. Regul Pept 1994; 54: 439-44
208. Luduron PM. Towards genomic pharmacology: from membranal to nuclear receptors. Adv Drug Res 1992; 22: 107-48
209. Cox HM, Cuthbert AW. The effects of neuropeptide Y and its fragments upon basal and electrically stimulated ion secretion in rat jejunum mucosa. Br J Pharmacol 1990; 101: 247-52
210. Cox HM, Krstenansky JL. The effects of selective amino acid substitution upon neuropeptide Y antisecretory potency in rat jejunum mucosa. Peptides 1991; 12: 323-7
211. Cox HM, Cuthbert AW, Hakanson R, et al. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia. J Physiol 1988; 398: 65-80
212. Higuchi H, Costa E, Yang H-YT. Neuropeptide Y inhibits the nicotine-mediated release of catecholamines from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1988; 244: 468-74
213. Schwartz TW, Fuhlendorff J, Kjems LL, et al. Signal epitopes in the three dimensional structure of neuropeptide Y. Ann NY Acad Sci 1990; 611: 35-47